Editor's Choice
Reports of asymptomatic monkeypox suggest that, at the very least, some infections go unnoticed.
1 Sep, 2022 | 11:54h | UTC
Guideline | Fecal immunochemical testing in patients with signs or symptoms of suspected colorectal cancer.
31 Aug, 2022 | 11:52h | UTCCommentary: Guidelines update: use of FIT in colorectal cancer referrals – PULSE
Review/Perspective | European hypertension guideline downgrading of beta-blockers is not justified.
31 Aug, 2022 | 11:51h | UTC
Systematic Review | Predictors of burnout among healthcare providers.
31 Aug, 2022 | 11:50h | UTCPredictors of burnout among US healthcare providers: a systematic review – BMJ Open
Commentary on Twitter
Workload, work/life balance, job autonomy and perceived support from leadership, have strong associations with risk for burnout in US healthcare providers. https://t.co/GjseiefjM7 pic.twitter.com/uisEcTs7Lk
— BMJ_Open (@BMJ_Open) August 25, 2022
RCT | Remote physician visits are noninferior to in-home physician visits for patients receiving acute hospital-level care at home (home hospital).
31 Aug, 2022 | 11:49h | UTCAuthor Interview: Remote vs In-home Physician Visits for Hospital-Level Care at Home – JAMA
Commentary on Twitter
Home hospital care is scaling fast, but the role for remote MD care is unknown. In this #RCT, remote MD care was noninferior to in-home MD care, but in-home MD care was critical to 1 in 5 patients. @hahusersgroup @WHAH_cong #OpenAccess #Research https://t.co/ZoE4oc37jx
— JAMA Network Open (@JAMANetworkOpen) August 30, 2022
RCT | Outpatient convalescent plasma therapy for high-risk patients with early COVID-19.
31 Aug, 2022 | 11:48h | UTC
#ESCCongress – M-A | Radial access for coronary interventions confers lower mortality than femoral access.
30 Aug, 2022 | 12:17h | UTCNews Release: Radial access for coronary interventions confers lower mortality than femoral access – European Society of Cardiology
Original Study: Impact on Mortality and Major Bleeding of Radial Versus Femoral Artery Access for Coronary Angiography or Percutaneous Coronary Intervention: a Meta-analysis of Individual Patient Data from Seven Multicenter Randomized Clinical Trials – Circulation (free for a limited period)
Commentary: Less Death, Major Bleeding With Transradial Access: Meta-analysis – TCTMD
Commentary on Twitter
#OriginalResearch SimPub #ESCCongress: In a individual-level meta-analysis of 21,600 patients undergoing coronary angiography, radial approach was associated with ⬇️ all-cause mortality (1.5 vs 2.1%) and ⬇️… @GargiuloG83 @vlgmrc @DanieleGiacoppo @SVRaoMD https://t.co/aOJ7ZgaJmK pic.twitter.com/gbWzUNTQck
— Circulation (@CircAHA) August 29, 2022
#ESCCongress | Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomized, double-blind trials.
30 Aug, 2022 | 12:16h | UTCNews Release: Cardiovascular protection from statins greatly outweighs the risk of muscle symptoms – European Society of Cardiology
Commentary: Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration – TCTMD
#ESCCongress – Meta-analysis of randomized trials | Angiotensin receptor blockers and Beta-blockers in Marfan syndrome: an individual patient data meta-analysis of randomized trials.
30 Aug, 2022 | 12:15h | UTCNews Release: Drug combination may delay need for surgery in patients with Marfan syndrome – TCTMD
Commentary: ARBs Halve Rate of Aortic Root Enlargement in Marfan: Meta-analysis – TCTMD
#ESCCongress – M-A | Patients with heart failure benefit from dapagliflozin regardless of ejection fraction.
30 Aug, 2022 | 12:14h | UTCNews Release: Patients with heart failure benefit from dapagliflozin regardless of ejection fraction – European Society of Cardiology
Related:
#ESCCongress | Study shows long-term Evolocumab appears to be safe in patients with established atherosclerotic cardiovascular disease.
30 Aug, 2022 | 12:12h | UTCNews Release: Long-term evolocumab therapy leads to further reductions in cardiovascular events – European Society of Cardiology
Original Article: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease – New England Journal of Medicine
Commentary on Twitter
#OriginalResearch SimPub #ESCCongress: In this open-label extension of #FOURIER RCT, long-term evolocumab therapy for >8 yrs was associated w/ persistently low rates and greater reduction in MACE compared w/ delayed treatment initiation among patients w… https://t.co/9g97s4MZSt pic.twitter.com/y5uN53gdKo
— Circulation (@CircAHA) August 29, 2022
#ESCCongress | In critically ill patients with COVID-19, full-dose anticoagulation reduced thrombotic events but increased the risk of bleeding.
30 Aug, 2022 | 12:12h | UTCNews Release: Trial supports full-dose anticoagulation to prevent blood clots in COVID-19 patients – European Society of Cardiology
Related:
Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library
Commentary on Twitter
#OriginalResearch SimPub #ESCCongress: In the #COVID-PACT 2×2 factorial RCT, full-dose prophylactic anticoagulation, but not the addition of clopidogrel, reduced thrombotic complications but w/ increased bleeding among critically-ill patients w/ COVID-19 https://t.co/UNxFCIC5B9 pic.twitter.com/p5LGmpCGeL
— Circulation (@CircAHA) August 29, 2022
#ESCCongress – RCT | In patients with severe ischemic left ventricular systolic dysfunction under optimal medical therapy, revascularization by PCI did not improve outcomes.
29 Aug, 2022 | 12:38h | UTCPercutaneous Revascularization for Ischemic Left Ventricular Dysfunction – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Coronary stenting does not benefit patients with severe left ventricular dysfunction – European Society of Cardiology
Commentary on Twitter
REVIVED-BCIS2: In patients with a low left ventricular ejection fraction and viable myocardium, PCI did not reduce the incidence of death from any cause or hospitalization for heart failure. #ESCCongress https://t.co/XtZlkJ7GAf pic.twitter.com/6uMNemzkyN
— NEJM (@NEJM) August 27, 2022
#ESCCongress – Meta-analysis of randomized trials | SGLT-2 inhibitors in patients with heart failure.
29 Aug, 2022 | 12:35h | UTCSGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials – The Lancet (free registration required)
Commentary on Twitter
Our meta-analysis of SGLT2 inhibitors in HF is now online in @TheLancet showing a
consistent reduction in the risk of CV death and HF hospitalisation in a broad range of 21,947
patients across range of EF and in different care settingshttps://t.co/qnxgayR235 pic.twitter.com/x0RsINoE9y— Kieran Docherty (@Kieranfdocherty) August 27, 2022
#ESCCongress – RCT | Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death in patients with heart failure with mildly reduced or preserved ejection fraction.
29 Aug, 2022 | 12:36h | UTCDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Dapagliflozin benefits patients with mildly reduced and preserved ejection fraction – European Society of Cardiology
Related (#ESCCongress 2021): RCT: SGLT2 inhibition reduced the combined risk of cardiovascular death or hospitalization in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.
Commentary on Twitter
DELIVER: In an RCT involving patients with HF and a mildly reduced or preserved ejection fraction, dapagliflozin reduced the risk of the composite outcome of worsening heart failure or CV death. #ESCCongress https://t.co/0umSDn5HkO pic.twitter.com/nq7zD2Fi2K
— NEJM (@NEJM) August 27, 2022
#ESCCongress – RCT | In patients with rheumatic heart disease–associated atrial fibrillation, treatment with a Vitamin K antagonist led to a lower rate of cardiovascular events or death compared to Rivaroxaban.
29 Aug, 2022 | 12:33h | UTCRivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Trial backs standard of care for rheumatic heart disease and atrial fibrillation – European Society of Cardiology
Commentary: INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF – TCTMD
Commentary on Twitter
INVICTUS: In patients with RHD-associated AF, compared to rivaroxaban, VKA reduced cardiovascular events and mortality without increasing bleeding. #ESCCongress https://t.co/4C45LmmB5o pic.twitter.com/9n3OelzZvp
— NEJM (@NEJM) August 28, 2022
[News release – not published yet] #ESCCongres – RCT | Evening dosing of blood pressure medication not better than morning dosing.
29 Aug, 2022 | 12:30h | UTCRelated Consensus Statement: Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension – Journal of Hypertension
Related study (conflicting results): Bedtime Hypertension Treatment Improves Cardiovascular Risk Reduction in Randomized Trial
#ESCCongress – RCT | Routine functional testing is not better than standard care in high-risk patients after percutaneous coronary intervention.
29 Aug, 2022 | 12:32h | UTCRoutine Functional Testing or Standard Care in High-Risk Patients after PCI – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
POST-PCI: In a randomized trial of patients who underwent percutaneous coronary intervention, routine stress testing did not improve clinical outcomes at two years. #ESCCongress https://t.co/nil00HQm4Z pic.twitter.com/o4v0UcDfYV
— NEJM (@NEJM) August 28, 2022
Bedtime dosing of antihypertensive medications: systematic review and consensus statement. – “use of bedtime drug dosing of antihypertensive drugs should not be routinely recommended”.
29 Aug, 2022 | 12:28h | UTC
RCT | Acetazolamide resulted in faster decongestion in patients with acute decompensated heart failure with volume overload.
29 Aug, 2022 | 12:25h | UTCAcetazolamide in Acute Decompensated Heart Failure with Volume Overload – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Acetazolamide improves decongestion in patients with acute decompensated heart failure – European Society of Cardiology
Commentary: Acetazolamide in Decompensated Heart Failure With Volume Overload – ADVOR – American College of Cardiology
Commentary on Twitter
https://twitter.com/NEJM/status/1563421082505588738
#ESCCongress | In patients within 6 months of a myocardial infarction, a polypill containing aspirin, ramipril, and atorvastatin resulted in a lower risk of major adverse cardiovascular events compared to usual care.
29 Aug, 2022 | 12:27h | UTCPolypill Strategy in Secondary Cardiovascular Prevention – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Polypill reduces cardiovascular events in heart attack patients compared to usual care – European Society of Cardiology
Commentaries:
Polypill Strategy Lowers Adverse CV Event Risk in Secondary Prevention – HCPLive
Related: M-A: Polypills with and without aspirin substantially reduce cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death in primary cardiovascular disease prevention. (several studies on the subject)
#ESCCongress – RCT | A large study with 46.611 individuals between 65 and 74 years of age found that a comprehensive cardiovascular screening program did not significantly reduce the incidence of death from any cause.
29 Aug, 2022 | 12:24h | UTCFive-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Cardiovascular screening may reduce risk of death and cardiovascular disease – European Society of Cardiology
Commentary on Twitter
DANCANVAS: In men age 65-74 years in Denmark, those randomized to invitation to comprehensive screening for subclinical CVD did not have signif reduced all-cause mortality at median 5.6 yrs of follow-up. #ESCCongress https://t.co/YZL87aTVHR pic.twitter.com/HfdiNuU9sK
— NEJM (@NEJM) August 27, 2022
Network Meta-Analysis | Antithrombotic therapy for symptomatic peripheral arterial disease.
26 Aug, 2022 | 13:28h | UTC
RCT | Self-measurement of blood pressure with a standard device is not enhanced by the use of a connected smartphone application.
26 Aug, 2022 | 13:29h | UTCEffectiveness of Standard vs Enhanced Self-measurement of Blood Pressure Paired With a Connected Smartphone Application: A Randomized Clinical Trial – JAMA Internal Medicine (link to abstract – $ for full-text)
News Release: For Checking Blood Pressure at Home, Basic Cuffs Are Just as Good – UC San Francisco
Commentary: App-enabled device no better than standard device for self-measuring blood pressure – ACP Internist
Commentary on Twitter
Monitoring #bloodpressure at home may help with #bloodpressurecontrol, but using an enhanced device pairing with a smartphone application appears to be no more effective than using a standard device. https://t.co/h6zREImCNv #Research pic.twitter.com/T1zWDlp2pC
— JAMA Internal Medicine (@JAMAInternalMed) August 15, 2022
Review | Incremental value of polygenic risk scores in primary prevention of coronary heart disease.
26 Aug, 2022 | 13:26h | UTCIncremental Value of Polygenic Risk Scores in Primary Prevention of Coronary Heart Disease: A Review – JAMA Internal Medicine (free for a limited period)
Related:
Cohort Study | Polygenic risk, midlife life’s simple 7, and lifetime risk of stroke.
AHA Scientific Statement | Polygenic risk scores for cardiovascular disease.
Cohort Study: A polygenic risk score may improve risk stratification of coronary artery disease.
Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps.